
The NPacers March 2022 Virtual Conference will cover topics in Primary Care and Pharmacology, along with industry symposiums from NPACE partners. Be sure to join NPACE on Wednesday, March 16th for a full day of continuing education!
Topics include Alzheimer’s, Glucose Monitoring, Managing Patients with CKD, Diabetes Risks, COPD, Psoriasis, Alopecia, Orthopedics, new treatment options in Gastroenterology, and optional IUD Training.
Don’t miss out on this one day event. Only $50! Now, earn up to 6 hours of CE.
Participant Disclaimer: Grubhub credits at NPACE events are issued based on each event’s requirements for earning Grubhub credit. For this virtual conference, participants can earn up to $75 in Grubhub credit for participating in Product Theater sessions. Grubhub may not be available to all NPACE participants due to limitations in geographic areas that Grubhub serves.
See all NPACE events
Speakers










Agenda
Wednesday, March 16, 2022
Sponsored non-CE
Speaker: Geraldine Francisco, NP-C, CDE
Describe the Progressive nature of CKD leading to significant morbidity and mortality.
Discuss the disease burden of CKD and importance of screening and diagnosis.
SGTL2i as recommended part of initial therapy in patients with T2D and CKD.
Overview of DAPA-CKD trial and trial endpoints.
Enduring access until April 16, 2022.
Sponsored CE
Speaker:
Wendy L. Wright DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP
Supported by an educational grant from Biogen.
Abstract:
Recent developments in the treatment of mild cognitive impairment and Alzheimer’s disease have created a lot of excitement…and confusion. This presentation will describe those recent developments and provide guidance in incorporating them into practice.
Learning Objectives:
At the end of the presentation, participants will be able to:
• Implement evidence-based methods for cognitive impairment screening in primary care.
• Identify correct diagnostic criteria for MCI and AD based on current guideline recommendations.
• Design appropriate and effective treatment plans for patients with MCI and AD and refer to a specialist when necessary.
• Describe advances in testing and treatment for AD that may impact dementia.
Enduring access until April 16, 2022.
Sponsored CE
Speaker:
Davida F. Kruger, MSN, APNBC, BCADM
Supported by an educational grant from Abbott Diabetes.
Abstract:
Continuous Glucose Monitoring is making a big impact on diabetes care – and patient outcomes. This presentation addresses many of the common questions asked by clinicians about CGM, including questions about data interpretation and obtaining coverage.
Learning Objectives:
At the end of the presentation, participants will be able to:
•Identify patients who are good candidates for a CGM versus fingerstick blood glucose monitoring.
•List the types of information provided by CGM systems.
•Locate and interpret CGM data using the Ambulatory Glucose Profile (AGP) to assess if the patients is achieving targets established by the International Consensus on Time in Range (TIR).
•Modify the treatment plan based on CGM data to improve patient outcomes.
Enduring access until April 16, 2022.
Sponsored non-CE, Sponsored by Boehringer-Ingelheim
Speaker: Javier Perez-Fernandez, MD, FCCM, FCCP
Live only.
Sponsored non-CE, Sponsored by Abbvie
Speaker: Brooks Cash, MD
Live only.
Please join us in a clinical review of exciting Phase 4 data and the latest post-marketing information on a proactive treatment that may help your IBS-D patients. IBS-D is a chronic functional disorder of the GI system that affects approximately 16 million people.
Company attribution: AbbVie
Sponsored CE
Speaker: Victoria (Tori) Garcia-Albea, NP, Lahey Clinic
Enduring access until April 16, 2022.
Overview/Program Description
· Title: Psoriasis and Psoriatic Arthritis for Advance Practice Providers
· Learn the pathophysiology of psoriatic disease, how to employ appropriate strategies to diagnose and treat comorbidities and approaches to collaborate as a healthcare team. Expand your knowledge of treatment approaches with helpful, case-based examples.
Learning Objectives
· Describe the pathophysiology of psoriatic disease.
· Review treatments and disease management.
· Employ appropriated strategies to diagnose and treat comorbidities associated with psoriatic disease.
The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Psoriasis Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation of the activity.
Disclosures
· Advisory Board – Sanofi Genzyme
Sponsorship
· This program is sponsored by AbbVie and supported by educational grants from Amgen, Bristol Myers Squibb, Janssen and Pfizer.
Sponsored CE, Sponsored by Med Learning Group
Speaker: Brett King, MD, PhD
Enduring access TBD.
This case-based live activity will cover the treatment of patients with Alopecia Areata (AA).
Learning Objectives:
– Explain the autoimmune mechanisms of current and emerging treatments for AA
– Determine which patients with AA are and are not candidates for JAK inhibitors
– Create treatment plans for patients with AA that address the comorbidities and psychosocial impacts of the disease
Audience:
This CME initiative is designed to meet the educational needs of dermatology professionals who care for patients with AA. The grand round is accredited for physicians for 1.0 AMA PRA Category 1 Credit(s)™. RNs and APNs will be awarded 1.00 contact hour(s) of continuing nursing education.
NPACE CE
Speaker: Christopher Hemmer, DNP, ANP, ONP-C, FAANP
Enduring access until April 16th, 2022.
Sponsored CE
Speaker: Christine Kessler, MN, ANP, CNS, BC-ADM, CDTC, FAANP
Enduring access until March 31st, 2022.
Please complete our pre-presentation survey. Copy and paste the following URL into a browser: https://wh1.snapsurveys.com/s.asp?k=163918154000
Participants can earn 1.0 CE Credit for participating in the PCEC partner program, “Optimizing the Benefits of GLP-1 RAs in T2DM.” This course is available until March 31st and must be completed by then to earn credit.
Abstract:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important element in the American Diabetes Association’s treatment algorithm for T2DM, yet they are under-prescribed. Learn about the benefits and limitations of GLP-1RAs and how they are making a difference in the lives of patients with T2DM.
Learning Objectives:
At the end of the activity, participants will be able to:
• Compare the glycemic and extra-glycemic profile of GLP-1RAs with other classes of medications for type 2 diabetes mellitus.
• Contrast the similarities and differences among currently available GLP-1RAs.•Select and optimize GLP-1RA therapy in collaboration with the patient to facilitate long-term patient self-management and adherence.
• Individualize GLP-1RA therapy for patients with T2DM and CV risk factors or established atherosclerotic cardiovascular disease as recommended by the ADA Standards of Medical Care in Diabetes – 2021.
Sponsored non-CE
Speaker: Havian Sterile, MSN, FNP-BC
Live only.
Requires separate registration. Virtual Conference registrants will receive instructions on how to register for Bayer IUD training. Deadline to register for IUD training is Friday, March 4.